Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

BRCA1/2-mutated and some sporadic triple-negative breast cancers (TNBC) have DNA repair defects and are sensitive to DNA-damaging therapeutics. Recently, three independent DNA-based measures of genomic instability were developed on the basis of loss of heterozygosity (LOH), telomeric allelic imbalan...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2016-08, Vol.22 (15), p.3764-3773
Hauptverfasser:	Telli, Melinda L, Timms, Kirsten M, Reid, Julia, Hennessy, Bryan, Mills, Gordon B, Jensen, Kristin C, Szallasi, Zoltan, Barry, William T, Winer, Eric P, Tung, Nadine M, Isakoff, Steven J, Ryan, Paula D, Greene-Colozzi, April, Gutin, Alexander, Sangale, Zaina, Iliev, Diana, Neff, Chris, Abkevich, Victor, Jones, Joshua T, Lanchbury, Jerry S, Hartman, Anne-Renee, Garber, Judy E, Ford, James M, Silver, Daniel P, Richardson, Andrea L
Format:	Artikel
Sprache:	eng
Schlagworte:	Allelic Imbalance Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor Female Genes, BRCA1 Genes, BRCA2 Homologous Recombination Humans Loss of Heterozygosity Mutation Neoplasm Staging Odds Ratio Platinum - administration & dosage Prognosis Telomere Treatment Outcome Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - genetics Triple Negative Breast Neoplasms - mortality Triple Negative Breast Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!